OpenAI released GPT-6 Rosalind Research on October 30 for biology and drug discovery, with access offered through a trusted-access program.

OpenAI released GPT-6 Rosalind Research on October 30, 2026, bringing GPT-6 reasoning to multistep biology, drug-discovery and translational-medicine work. It is rolling out to approved research organizations through a trusted-access program, in Work, Codex and the API—not ChatGPT’s Chat tab; the API model name is `gpt-6-rosalind`. OpenAI says Rosalind uses the same weights as GPT-6 Astra but has fewer refusals on dual-use biology queries, while retaining safeguards against assistance that could enable biological weaponization. The company rates its biological and chemical capability High, below Critical, and retains Astra’s Critical cybersecurity rating. On OpenAI’s internal tests, it scored 49.6% on MedChemBench v7 (99 tasks), versus 28.9% for GPT-5.5 Rosalind; 37.7% on GeneBench Pro v13 (129 tasks), versus 16.7%; and 61.3% on LifeSciBench Gold (94 tasks), versus 44.0%. These small, company-run evaluations are not proof of drug success. The launch extends OpenAI’s existing Rosalind life-sciences offering: GPT-5.